Insulin Pump and CGM Leader MiniMed(MMED.US) Debuts on U.S. Stock Market, "Medtronic Halo" Fails to Offset Growth Concerns

Bloomberg News has learned that MiniMed Group Inc., a diabetes management company soon to be spun off from the American healthcare giant Medtronic Plc, successfully raised approximately $560 million through its initial public offering (IPO) in the United States. However, the offering price was below its previous expected range, highlighting a discount in the healthcare technology niche market and market concerns about Medtronic’s valuation of MiniMed and its future growth prospects. According to a statement on Thursday, this leading U.S. healthcare company sold 28 million shares at $20 per share. An earlier unamended filing indicated that the company had planned to set the offering price between $25 and $28 per share.

Based on this latest IPO price, the California-based healthcare company’s preliminary market capitalization would be about $5.6 billion, based on the number of shares outstanding listed in the filing. MiniMed’s main business focuses on selling automated insulin pumps, continuous glucose monitors (CGMs), and smart insulin pens.

As a diabetes management unit under Medtronic, its product line mainly includes the MiniMed series of fully automated insulin pumps, CGMs, and smart insulin pens, all independently designed, developed, and manufactured by MiniMed / Medtronic, not just as agents or resellers.

Flagship products like the 780G and 670G automated insulin delivery systems are based on the company’s proprietary technology platform. These devices integrate sensors, control algorithms, and hardware terminals, achieving automated insulin management through closed-loop control technology, and have received FDA approval and clinical application worldwide. MiniMed’s core operations encompass product R&D, clinical validation, manufacturing, and marketing, all based on its own medical technology and product achievements, rather than relying on third-party brands or traditional OEMs.

This diabetes-focused organization is set to spin off after nearly 25 years of collaboration with Medtronic, according to a letter included in the CEO Que Dallara’s statement in the filing.

The proposed IPO valuation has sparked debate among Wall Street analysts about whether its growth prospects can justify these low figures. According to MarketPro’s adjusted EBITDA, the company’s potential valuation appears very inexpensive compared to other publicly listed companies such as Dexcom Inc., Insulet Corp., and Tandem Diabetes Care Inc., with MiniMed representing a significant discount.

In the six months ending October 24, MiniMed reported total revenue of approximately $1.5 billion and a net loss of about $21 million. In comparison, the same period last year saw revenue of around $1.3 billion and a net loss of $23 million, indicating a narrowing of losses but no strong revenue growth.

MiniMed plans to use part of the funds to pay down substantial debt owed to Medtronic, according to disclosures in the filing.

Goldman Sachs, Bank of America, Citigroup, and Morgan Stanley are the main underwriters for this offering. The company’s stock was priced on the NASDAQ and will subsequently trade on the NASDAQ Global Select Market under the ticker MMED.

Although the diabetes device segment—such as insulin pumps and continuous glucose monitoring systems—has long-term growth potential (benefiting from aging populations and chronic disease management needs) and technological accumulation, investors are clearly cautious about its valuation and outlook, and there has been no widespread rush for funds. The MiniMed IPO was priced below the previously expected range, reflecting a lack of overheating demand for such niche healthcare stocks.

This cautious market attitude is largely driven by recent geopolitical tensions in the Middle East, which have sharply reduced risk appetite, as well as the long-standing low-risk exposure and market conditions in the medical device industry: on one hand, MiniMed has shown only modest revenue growth in recent quarters and still reports net losses, indicating an unstable profit path; on the other hand, its valuation is viewed as discounted compared to peers like Dexcom and Insulet, demonstrating a more cautious approach by capital markets when assessing growth and risk.